For early stage (stages I/II) CRC detection, ColoDefense test showed 80.0% and 90.0% sensitivities, significant higher than that of methylated SDC2 alone (55.0% and 74.0%) or methylated SEPT9 alone (65.0% and 84.0%). The gene discussed is SDC2; the disease is colorectal carcinoma.